Oligo Splicing and Chemical Modification

BOC Sciences has the expertise and capability to provide oligonucleotide modification services to clients worldwide. BOC Sciences' state-of-the-art facilities, advanced technology and experienced staff can provide you with a full range of splicing and chemical modifications to meet your biological, diagnostic and drug discovery needs.


  • Splicing

Splicing refers to the editing of newly transcribed pre-messenger RNA (pre-mRNA) by removing introns (non-coding regions of the gene) and adding or joining exons (coding regions). Mature mRNA is thus created, which is then used as a template for the synthesis of specific proteins.

  • Splice-switching oligonucleotides (SSOs)

SSOs are short, synthetic, antisense, modified nucleic acids that base pair with pre-mRNA and disrupt the normal splicing repertoire of transcripts by blocking protein-RNA binding interactions between RNA-RNA base pairing or splicing units and pre-mRNA. SSOs support an effective and specific way to therapeutically target and alter splicing. Modifications in SSOs involve altering the phosphate backbone and/or sugar component of the oligonucleotide and adding chemical modifications aimed at altering splicing rather than causing degradation of the bound pre-mRNA.

Our Oligo Splicing and Chemical Modification Services Specification

Phosphorodiamidate morpholino (PMO) oligo modificationPMO has a morpholine ring to replace the furanose ring in native nucleic acids and a neutral phosphodiester backbone to replace the negatively charged phosphodiester backbone. The neutral charge of PMO results in low binding to plasma proteins, which improves tolerance in vivo.Inquiry
2'-O-methyl-phosphorothioate (2'-OMePS) oligo modificationThe 2'-hydroxyl group of the 2'-OMePS ribose ring is replaced by a 2'-O-2-methoxyethyl and phosphate linkage. This modification makes it more stable in vivo, less susceptible to breakdown by nucleases, and still maintains its base-pairing function.Inquiry
LNA/ Amido-bridged nucleic acid (AmNA)/ Guanidine-bridged nucleic acid (GuNA) modificationLNA is a nucleotide analogue carrying an altered ribose in which a methylene bridge links the 2'-O to the 4'-C atom in the furanose ring. This bridge allows LNA to form a strict N-type conformation, thus promoting binding affinity to complementary RNAs. Both AmNA-modified SSO and GuNA-modified SSO exhibited higher exon skipping activity and efficient splicing regulation.Inquiry

Why Choose Us

  • High-quality products
  • competitive price
  • Data analysis, detailed reporting including results and discussion
  • Guaranteed total yield per oligonucleotide is a fixed final yield of OD units
  • All samples are carefully monitored for stability and characterized to ensure batch-to-batch consistency


  1. Roberts, T.C.; et al. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020. 19(10): p. 673-694.
  2. Nan, Y; et al. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Front Microbiol. 2018. 9: p. 750.
  3. Pires, V.B.; et al. Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in duchenne muscular dystrophy myotubes. PLoS One. 2017. 12(7): p. e0181065.
  4. Shimo, T.; et al. Design and in vitro evaluation of splice-switching oligonucleotides bearing locked nucleic acids, amido-bridged nucleic acids, and guanidine-bridged nucleic acids. Int J Mol Sci. 2021. 22(7).
* Only for research. Not suitable for any diagnostic or therapeutic use.
Online Inquiry
Verification code
Event information
Inquiry Basket